Exelixis Inc. has announced the initiation of a Phase 1 clinical study for XB628, a groundbreaking bispecific antibody designed to treat participants with recurrent advanced or metastatic solid tumors. This first-in-human study marks a significant milestone in the collaboration between Exelixis and Invenra Inc., which was instrumental in discovering this innovative molecule. XB628 functions as a natural killer (NK) cell engager, targeting the inhibitory receptor NKG2A on NK cells and the programmed cell death-ligand 1 (PD-L1). The study aims to evaluate the safety and dosage levels of XB628, potentially offering a new therapeutic option for patients with challenging cancer types.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.